Sudeep Pharma AGM: Shareholders approve battery expansion, FY26 results
Sudeep Pharma Limited reported FY26 revenue of ₹642.3 crore and PAT of ₹174.3 crore at its 37th AGM. Shareholders approved the company's expansion into advanced battery materials, new board appointments, and the ratification of the employee stock option scheme. The Specialty Ingredients segment drove growth with a 63% increase, while the company maintains a low net debt-to-equity ratio of 0.04.
*this image is generated using AI for illustrative purposes only.
Sudeep Pharma Limited shareholders adopted the audited standalone and consolidated financial statements for the fiscal year ended March 31, 2026, during the company’s 37th Annual General Meeting held on August 4, 2026. The meeting, conducted via Video Conferencing/Other Audio-Visual Means (VC/OAVM), served as the primary forum for approving the company’s strategic pivot into advanced battery materials alongside its core pharmaceutical and nutrition business. The adoption of these results confirms the company’s highest-ever revenue from operations of ₹642 crore, underpinned by a 63% surge in its Specialty Ingredients segment.
The proceedings were held in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Dimple Mehta, Company Secretary & Compliance Officer, confirmed that the requisite quorum was present. The statutory auditors, B S R and Co., Chartered Accountants, and secretarial auditors, H M Mehta & Associates, were present. Mr. Hemang Mehta of H M Mehta & Associates was appointed as the scrutinizer for the e-voting process. The voting facility remained open until 11:42 a.m. IST, following the conclusion of the meeting at 11:27 a.m. IST.
Financial Performance and Segment Growth
Management highlighted that FY26 was a landmark year characterized by disciplined execution and significant capacity expansion. Revenue from operations reached ₹642.3 crore, driven largely by the Specialty Ingredients segment, which grew by 63% to ₹280 crore. This segment now accounts for approximately 44% of total revenue, up from 34% in the previous year. The Pharmaceutical, Food and Nutrition business contributed ₹362 crore, representing 56% of total revenue, with growth constrained by optimal utilization of existing facilities.
| Financial Metric | Value |
|---|---|
| Revenue from Operations | ₹642.3 crore |
| EBITDA | ₹221.9 crore |
| Profit After Tax | ₹174.3 crore |
| EBITDA Margin | 34.6% |
| PAT Margin | 27.1% |
| Net Debt | ₹33.6 crore |
| Net Debt-to-Equity | 0.04 |
Exports remained a core strength, contributing approximately 60% of total revenue. The company maintained a strong balance sheet with net debt of ₹33.6 crore and a net debt-to-equity ratio of just 0.04. Management noted that return ratios moderated due to investments in new capacity, the integration of NSS in Ireland, and the deployment of IPO proceeds.
Strategic Expansion into Advanced Materials
A key focus of the AGM was the company’s entry into the electric vehicle and energy storage ecosystem through Sudeep Advanced Materials. Leveraging over a decade of expertise in iron phosphate chemistry for nutrition applications, the company is applying this science to battery-grade materials. Construction of the Phase I facility at Dahej is progressing as planned, with an annual capacity of 25,000 metric tonnes and commissioning targeted for April 2027.
The company reported engaging with 42 global customers across the EV, battery cell, cathode material, and energy storage sectors. Several customers are advancing through laboratory validation and pilot evaluation, resulting in initial commercial orders of approximately 700 metric tonnes. To serve early demand ahead of the Dahej commissioning, Sudeep Pharma upgraded an existing line to manufacture battery-grade material. This diversification aims to create multiple engines of growth beyond traditional mineral-based ingredients.
Governance and Board Appointments
Shareholders approved several special resolutions to support long-term governance and growth strategies. The assembly ratified the remuneration for Cost Auditors for FY27 and appointed Mr. Hemang Mehta as Secretarial Auditor for a term of five consecutive years. Mr. Milin Mehta was appointed as a Non-Executive, Non-Independent Director. Additionally, shareholders approved the re-appointment of Mr. Ajay Shrirang Kandelkar as a director retiring by rotation and approved a change in his remuneration as Whole Time Director effective April 1, 2026.
The meeting also saw the ratification of the 'Sudeep Pharma Employee Stock Option Scheme 2025' and the approval to grant options to eligible employees of subsidiary and group companies. A new set of Articles of Association was adopted to align with evolving corporate requirements. There were no qualifications or adverse remarks in the Statutory Auditor’s Report or the Secretarial Audit Report, indicating clean compliance across all audited areas.
Historical Stock Returns for Sudeep Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.48% | +1.60% | +0.43% | +43.04% | +12.61% | +12.61% |
How will the commissioning of the Dahej facility in April 2027 impact Sudeep Pharma's EBITDA margins compared to its current pharmaceutical core business?
What specific regulatory hurdles or certification processes must Sudeep Advanced Materials clear to secure larger-scale contracts from global EV manufacturers beyond the initial 700 metric tonnes?
Given the 63% surge in Specialty Ingredients, what are the primary drivers for this growth, and is this segment poised to surpass the Pharmaceutical and Food business as the largest revenue contributor in FY27?
19
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
